UK-BASED SUPPLIER · ESTABLISHED 2023
Research-grade peptides, verified by third-party analysis.
Supplied to independent researchers, academic laboratories, and accredited institutions. Purity verified by HPLC and mass spectrometry on every batch.
≥98%
HPLC PURITY
2pm
DISPATCH CUT-OFF
-20°C
COLD CHAIN
COA
PER BATCH
Most studied compounds
Latest from the peptide industry
Research Pipeline
TRIUMPH-4 read-out: retatrutide hits 28.7% weight loss but a new dysesthesia signal complicates the path to filing
Eli Lilly's triple-agonist retatrutide produced the highest weight-loss percentage ever recorded in a Phase 3 obesity trial in TRIUMPH-4, but a new dysesthesia signal — not seen in Phase 2 — affected one in five patients on the top dose. With seven further Phase 3 read-outs scheduled across 2026, the next nine months will determine whether retatrutide rewrites the GLP-1 competitive map or carries a safety footnote into the label.
18 May 2026
Industry & Community
Macrocyclic Peptides Draw Wave of Institutional Capital in 2026 as Big Pharma Targets "Undruggable" Biology
A cluster of deals in early 2026 has placed macrocyclic peptides at the centre of pharmaceutical dealmaking, with Syneron Bio closing a $150 million Series B, Novartis committing up to $1.8 billion to Unnatural Products, and AstraZeneca holding a strategic stake in the macrocycle space. For research-procurement teams, the surge signals where institutional confidence in the peptide modality is moving.
15 May 2026
Research Pipeline
Foundayo (Orforglipron) Sustains Most Injectable GLP-1 Weight Loss in Phase 3b Switch Trial, New Data Show
A Phase 3b trial published in Nature Medicine on 12 May 2026 shows that patients who switched from injectable tirzepatide or semaglutide to once-daily oral orforglipron (Foundayo) retained 75–79% of their prior weight loss over 52 weeks. The data, presented simultaneously at the European Congress on Obesity, add clinical depth to an already-approved drug and sharpen the debate over whether oral small-molecule GLP-1 agonists can serve as maintenance therapy after injectable induction.
15 May 2026
Every batch, documented.
HPLC purity analysis, mass spectrometry confirmation, and batch traceability — downloadable per product, matched to the batch code on your vial.
View our methodology →
Cold chain maintained.
Lyophilised product held at -20°C in temperature-controlled storage from receipt to dispatch. Stability guaranteed under documented conditions.
Storage protocols →
Same-day, plain packaging.
Orders placed before 2pm dispatched the same working day. Tracked UK delivery, discreet unbranded packaging as standard.
Shipping & returns →